WallStSmart
VKTX

Viking Therapeutics Inc

NASDAQ: VKTX · HEALTHCARE · BIOTECHNOLOGY

$29.63
+3.06% today

Updated 2026-06-15

Market cap
$3.34B
P/E ratio
P/S ratio
EPS (TTM)
$-4.15
Dividend yield
52W range
$23 – $43
Volume
2.2M

Viking Therapeutics Inc (VKTX) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item20122013201420152016201720182019202020212022202320242025
Operating cash flow$-200.00$-78235.00$-1.59M$-8.73M$-11.07M$-14.76M$-18.75M$-24.75M$-21.78M$-47.59M$-48.40M$-73.38M$-87.79M$-278.69M
Capital expenditures$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Depreciation
Stock-based comp$22.00$3.00$6258.00$2.60M$1.79M$1.45M$2.61M$3.74M$5.82M$6.10M$8.67M$16.75M$29.71M$40.82M
Free cash flow$-200.00$-78235.00$-1.59M$-8.73M$-11.07M$-14.76M$-18.75M$-24.75M$-21.78M$-47.59M$-48.40M$-73.38M$-87.79M$-278.69M
Investing cash flow
Financing cash flow
Dividends paid$0.00$22288.00$0.00
Share repurchases
Debt repayment
Net change in cash$12693.00$2.31M$5.91M$15.79M$-16.40M$20.74M$-2.75M$10.52M

Frequently asked questions

How much free cash flow does VKTX generate?

VKTX produced $-278.69M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is VKTX's balance sheet healthy?

VKTX holds $165.81M in cash and equivalents against — in long-term debt, on $639.06M of shareholder equity. That debt is best read against the cash flow the business throws off each year.